Imricor Medical Systems, Inc. · ASX:IMR
Imricor Medical Systems — Q3 2026 Earnings Presentation
19 slides from Imricor Medical Systems's earnings presentation, Nov 13, 2026
Slide 1: Q3 Result Webinar Presentation
r personal use only Q3 Result Webinar Presentation November 13, 2026 Imricor's vision is to bring iMR to every cardiac centre in the world IMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) WWW.IMRICOR.COM 1
Slide 2: Disclaimer
Disclaimer r personal use only The material contained in this document is a presentation of general background information on assumptions which are, in many instances, beyond its control, and have been made based upon Imricor Medical Systems, Inc. (Imricor) and its activities current as of the date
Slide 3: Imricor – more than a medical device company
Imricor – more than a medical device company r personal use only A technology platform that is establishing a new medical field: interventional MR (iMR) FIELD iMR Interventional MR: a new medical field PROCEDURES Electrophysiology Cardiac catheterisation Future interventions Atrial flutter, AFib and
Slide 4: U.S. commercial launch underway
U.S. commercial launch underway r personal use only Q3 CY2026 Highlights 2 US$188k 14 of 15 US$62.1m / A$90m* FDA U.S. hospital customers, both leading submissions for full U.S. platform Revenue, up 437% on pcp Cash at 30 September 2026 children's hospitals complete or under review U.S. commercial l
Slide 5: Financial Performance
Financial r personal use only Performance IMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) WWW.IMRICOR.COM 5
Slide 6: Profit and loss
Profit and loss r personal use only US$’000 Q3 2026 Q3 2025 Commentary Revenue 188 35 • Revenue up 440% on prior comparative period (pcp) as the U.S. launch commences. Costs and non-R&D expenses (4,000) (3,119) • Costs and non-R&D expenses increased primarily due to R&D expenses (4,220) (2,507) staf
Slide 7: Balance sheet
Balance sheet r personal use only US$’000 30 Sep 2026 31 Dec 2025 Commentary Cash and cash equivalents 62,100 19,502 Marketable securities - 21,278 • Cash and cash equivalents total US$62.1 million/A$90m Accounts receivable 379 241 • Convertible note held at fair value under US GAAP; Inventory 1,914
Slide 8: Cash flow
Cash flow r personal use only US$’000 Q3 2026 Q3 2025 Commentary Net loss (2,910) (3,494) • Other non-cash adjustments decrease vs. pcp primarily due Other non-cash adjustments (3,311) (1,345) • Decreases in the change in fair value charges; • Partially offset by increases in stock-based Change in o
Slide 9: Regulatory progress of submissions completed
r personal use only Regulatory progress 14 of 15 submissions completed IMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) WWW.IMRICOR.COM 9
Slide 10: Regulatory progress: FY25 result vs November
Regulatory progress: FY25 result vs November 26 r personal use only 20 years of work nearing completion UNITED STATES — device / submission Pathway STATUS AT FY25 RESULT (Feb 2026) STATUS TODAY (Nov 2026) NorthStar 510(k) CLEARED CLEARED Vision-MR Diagnostic Catheter 510(k) CLEARED CLEARED Vision-MR
Slide 11: Click to watch video
x r personal use only Click to watch video IMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) WWW.IMRICOR.COM 11
Slide 12: Philips Partnership: Commercial Launch of the iMR Lab Solution
Philips Partnership : Commercial Launch of the iMR Lab Solution r personal use only Imricor and Philips leadership at the joint iMR lab solution launch Signing the combined iMR lab solution agreement, ESC Congress 2026 • Fourteen years of joint development - now a commercial iMR lab solution that Ph
Slide 13: We are not alone in our thinking or execution
We are not alone in our thinking or execution r personal use only iMR Lab Solution Video Click to watch video -Interventional Cardiac MR Solution - Philips WWW.IMRICOR.COM IMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) 13
Slide 14: We are not alone in our thinking or execution
We are not alone in our thinking or execution r personal use only • Years of Philips development behind the interface • NorthStar controls the MR scanner and receives images in real time • Tracks Imricor’s active catheters inside the patient IMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) 14
Slide 15: We are not alone in our thinking or execution
We are not alone in our thinking or execution r personal use only • 7 liters of sealed helium, vs ~1,500 liters in a conventional scanner • Light enough for upper floors, e.g. the cardiology center • No quench pipe, so no external wall needed • Wide bore at 1.5T: patient access without losing image
Slide 16: We are not alone in our thinking or execution
We are not alone in our thinking or execution r personal use only • Philips is backing iMR with its brand and sales force • Imricor products feature throughout the lab • More Imricor technology sits in the control room IMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) 16
Slide 17: We are not alone in our thinking or execution
We are not alone in our thinking or execution r personal use only • Philips’ own message, not Imricor’s • Imricor’s view for 20 years, now shared by Philips IMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) 17
Slide 18: We are not alone in our thinking or execution
We are not alone in our thinking or execution r personal use only • First international meeting devoted entirely to interventional MR (iMR) • Organized by the medical community, not Imricor; Imricor and Philips are co-sponsors • Physicians worldwide are adopting iMR, with Imricor at the center of th
Slide 19: Summary and Q&A
Summary and Q&A r personal use only INVESTMENT HIGHLIGHTS 1 Global leader in MR conditional systems and devices 2 US$15bn market growing at 15% 3 No competition 4 Safety tailwinds with rising concerns about radiation exposure 5 Close partnerships with MR manufacturers 6 Strong balance sheet: US$62m
Imricor Medical Systems — Q3 2026 Earnings Presentation on 6ix